Given the lack of established drug therapies for cancer cachexia, the design, implementation and analysis of the PROACC‐1 study will evaluate the potential role of ponsegromab in patients with cancer, cachexia and elevated concentrations of GDF‐15 and will help inform whether larger scale pivotal trials testing ponsegromab are warranted. Here, GDF15 is linked to cancer.